NEWS

AegirBio receives second milestone payment under RadX NIH

Lund June 11, 2024 – AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today the company has received its second milestone-based payment of USD 180,829 under the RadX NIH program. In May, AegirBio received the first milestone payment of USD 148,026 under this agreement. The milestones validate AegirBio’s unwavering dedication to pioneering research and development.

"At AegirBio, we are committed to pushing the boundaries of innovation and fostering positive change in healthcare. The payments from RadX NIH reflect the tireless efforts of our team," said Marco Witteveen, CEO of AegirBio.

As we celebrate this milestone, our commitment to advancing with RadX remains unwavering. With ongoing support from initiatives like RadX NIH and the expertise of our talented team, we are positioned to drive significant progress and make meaningful contributions to the field.

For additional information, please contact:

Marco Witteveen, CEO, AegirBio AB
Email: ir@aegirbio.com

About AegirBio:

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se

Attachments:
AegirBio receives second milestone payment under RadX NIH